Skip to main content

and
  1. Article

    Open Access

    The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

    Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodiu...

    Michael E. Nassif, Sheryl L. Windsor, Barry A. Borlaug in Nature Medicine (2021)

  2. Article

    Open Access

    Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

    In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (H...

    Barry A. Borlaug, Dalane W. Kitzman, Melanie J. Davies, Søren Rasmussen in Nature Medicine (2023)